Clinical Trials Logo

NEBULIZATION clinical trials

View clinical trials related to NEBULIZATION.

Filter by:
  • None
  • Page 1

NCT ID: NCT06291740 Not yet recruiting - Clinical trials for Emergency Department

Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical is to compare treatment outcomes between continuous nebulization and intermittent therapy in the management of acute exacerbation of asthma in the emergency department(ED). Participants will random assign to either continuous or intermittent nebulization. In the continuous group, patients receive budesonide, fenoterol, ipratropium bromide, and normal saline continuously for an hour. In the intermittent group, the same medications are administer every 20 minutes for an hour. Measurements include symptom severity, respiratory rate, oxygen saturation, and pulmonary function tests. Primary endpoints are ED stay length, hospital admission, and ED revisit within 48 hours post-discharge. Adverse events are documented.

NCT ID: NCT06226402 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Effect of Nebulized and Intravenous Hypertonic Saline 3% on the Management of Patients With Acute Respiratory Distress Syndrome

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The aim of our study is to compare between the effect of nebulized and intravenous injection of hypertonic saline 3% on the outcome of patients with acute respiratory distress syndrome.

NCT ID: NCT06088875 Recruiting - Dexmedetomidine Clinical Trials

Nebulization Versus Spray-as-You-Go Airway Topical Anesthesia Using Dexmedetomidine and Lidocaine Mixture During Awake Flexible Fiberoptic Intubation in Temporomandibular Ankylosis

Start date: October 18, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to compare the efficacy of airway topical anesthesia with nebulization to the spray-as-you-go technique using dexmedetomidine and lidocaine mixture to achieve upper airway anesthesia in TMJ ankylosis patients.

NCT ID: NCT04469491 Completed - COVID-19 Clinical Trials

Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

COV-NI
Start date: September 20, 2020
Phase: Phase 2
Study type: Interventional

COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date, no treatment has yet demonstrated Strong efficacy in treating the infectious disease (COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high potential,due to higher local concentrations and minimal adverse effects. Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators have a decrease in viral carriage and a rapid reversal. The purpose of this project is to assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements of the addition of inhaled Interferon type I compared to the control arm .